Welcome to our dedicated page for VSee Health SEC filings (Ticker: VSEE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The VSee Health, Inc. (NASDAQ: VSEE) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a telehealth technology and services company in the health information services sector, VSee uses its filings to report on business operations, capital structure, financing arrangements, and Nasdaq listing matters.
Investors can review annual reports on Form 10-K and quarterly reports on Form 10-Q for information on VSee’s healthcare technology and telehealth services segments, revenue composition, costs, and risk factors. These core filings outline how the company describes its AI-powered telehealth platform, high-acuity virtual care services, and digital health offerings that integrate secure video, device data, and EHR connectivity for hospital systems, health networks, employers, and enterprise partners.
VSee’s current reports on Form 8-K document material events such as private placements of common stock and warrants, convertible note agreements, warrant exchanges, equity line of credit arrangements, and amendments tied to Nasdaq stockholders’ equity requirements. Recent 8-K and 8-K/A filings describe steps the company has taken to address Nasdaq Listing Rule 5550(b)(1), including capital transactions and conversions of outstanding instruments, as well as governance items like annual meeting scheduling and bylaw amendments affecting quorum.
Through this page, users can also locate proxy materials on Schedule 14A, which detail proposals for director elections, auditor ratification, equity incentive plans, and adjournment authority, along with information on voting rights for common and preferred stock. For those monitoring ownership and compensation, insider transactions and related disclosures can be reviewed via the relevant SEC forms where available.
Stock Titan enhances these filings with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly understand complex capital structures, financing terms, and operational disclosures without replacing the full text of the official filings.
VSee Health, Inc. registers 33,808,195 shares of Common Stock for resale by the named selling stockholders.
The registration consists of 3,000,000 Manatt Shares, up to 1,300,000 Series B Shares issuable upon conversion, 9,836,065 pre-funded warrant shares and 19,672,130 warrant shares. Shares outstanding were 47,299,421 as of March 30, 2026. The supplement incorporates the Form 10-K for the fiscal year ended December 31, 2025 and updates the prospectus; resale activity is by the selling stockholders.
VSee Health, Inc. filed a Post-Effective Amendment No. 1 to its Form S-1 (Registration No. 333-292464) under Rule 462(d) to include auditor consents. The amendment is exhibits-only and adds the consents of WWC, P.C. and WithumSmith+Brown, P.C. related to the consolidated financial statements for the year ended December 31, 2025.
VSee Health, Inc. files its annual report describing a telehealth software platform and high-acuity critical care services alongside significant losses and going‑concern risks. The company reported operating losses of $9,582,893 in 2025 and $62,150,845 in 2024, with an accumulated deficit of $82,416,723 as of December 31, 2025. Its auditor highlighted substantial doubt about VSee’s ability to continue as a going concern due to ongoing losses and negative operating cash flows.
VSee delivers configurable, no‑code and low‑code telehealth tools through VSee Lab and tele‑ICU and specialty physician services through iDoc, targeting hospital systems, ICUs, correctional facilities and other high‑acuity settings. Competition is intense from large telehealth vendors, EMR‑embedded tools and in‑house solutions. The company faces heavy regulatory exposure, including HIPAA, state privacy rules, anti‑kickback and self‑referral laws, False Claims Act risk and evolving Medicare/Medicaid telehealth reimbursement. VSee also depends heavily on a small number of major customers and approximately 93 board‑certified physicians within a 209‑person workforce.
Leonard Jerry reported acquisition or exercise transactions in this Form 4 filing.
VSEE HEALTH, INC. Chief Financial Officer Leonard Jerry received multiple grants of common stock as equity compensation. On March 23, 2026, he was awarded grants including 66,845 shares at $0.37, 40,984 shares at $0.61, 21,552 shares at $1.16, and 20,833 shares at $1.20 per share.
Footnotes explain these shares were issued under the 2024 Incentive Plan as quarterly equity awards owed for the quarters ended March 31, June 30, September 30, and December 31, 2025, with each grant amount based on the common stock closing price on the respective quarter-end date.
Aisiku Imoigele reported acquisition or exercise transactions in this Form 4 filing.
VSee Health, Inc. director and Co-Chief Executive Officer Aisiku Imoigele reported receiving four quarterly equity awards of common stock under the company’s 2024 Incentive Plan, all dated March 23, 2026 and tied to 2025 quarters. The grants cover 128,342 shares at $0.37 per share, 78,689 shares at $0.61, 41,379 shares at $1.16, and 40,000 shares at $1.20, issued as stock compensation pursuant to his executive employment agreement.
O'SULLIVAN COLIN P. reported acquisition or exercise transactions in this Form 4 filing.
VSEE HEALTH, INC. director Colin P. O'Sullivan reported an award of 40,107 shares of common stock, granted under the company’s 2024 Incentive Plan as compensation for his board service for the quarter ended December 31, 2025.
The number of shares was based on the common stock closing price on December 31, 2025, and after this grant he directly owns 108,731 shares of VSEE common stock.
METZGER SCOTT reported acquisition or exercise transactions in this Form 4 filing.
VSEE Health, Inc. director Scott Metzger received a grant of 40,107 shares of common stock at $0.374 per share. This equity award was issued under the company’s 2024 Incentive Plan as compensation for his service as a non-employee director for the quarter ended December 31, 2025.
After this grant, Metzger directly holds a total of 117,356 shares of VSEE Health common stock. The number of shares granted was determined using the common stock’s closing price on December 31, 2025.
VSEE HEALTH, INC. director Kevin Lowdermilk acquired 40,107 shares of common stock at a price of $0.374 per share. These shares were issued under the company’s 2024 Incentive Plan as compensation for his board service for the quarter ended December 31, 2025, based on the stock’s closing price that day. Following this grant, he directly holds 108,731 common shares.
WICKERSHAM DAVID L. reported acquisition or exercise transactions in this Form 4 filing.
VSEE HEALTH, INC. director David L. Wickersham reported an equity award of 40,107 shares of common stock on March 4, 2026. The award was issued under the company’s 2024 Incentive Plan as compensation for his services as a non-employee director for the quarter ended December 31, 2025, with the number of shares based on the closing price of the common stock on December 31, 2025.
After this grant, Wickersham directly holds 1,187,671 shares of VSEE common stock.
VSEE HEALTH, INC. director Fairfax Cydonii V. acquired 40,107 shares of common stock as a stock grant under the company’s 2024 Incentive Plan, issued for services as a non-employee director for the quarter ended December 31, 2025. The grant was based on the common stock’s $0.374 closing price on December 31, 2025 and increased the director’s directly held stake to 108,504 shares of common stock.